with associated significant neurological sequelae would seem to be relatively rare. Only nine cases of epidural haematoma with neurological complications have been reported in the world literature since 1961. 6 • 7 Significant bleeding, however, could be associated with potentially irreversible neurological damage and it is, therefore, important to minimise this risk.
This twelve-month prospective study was undertaken to confirm or refute reports of a platelet function deficit in pre-eclampsia and to establish whether it is necessary to do a bleeding time on all such patients prior to regional blockade.
MATERIALS AND METHODS
A twelve-month prospective descriptive study of pre-eclamptic patients admitted to the Royal Hospital for Women, Sydney, was undertaken.
All patients admitted to the hospital during the trial period were considered suitable for study if they fulfilled the following criteria: 1. systolic blood pressure> 140 mmHg and diastolic blood pressure> 90 mmHg; 2. proteinuria> 1 gll; and 3. no pre-existing hypertension, renal disease or other disorder predisposing to the development of hypertension in pregnancy.
Informed consent was obtained from all patients and the study was approved by the hospital's Human Studies and Medical Ethics Committee.
Forty pre-eclamptic patients were studied. The results available from eight thirdtrimester non pre-eclamptic patients and the hospital's laboratory control values for pregnant patients ofthe appropriate gestation were used as normal reference.
The systolic and diastolic arterial pressures were measured using a mercury sphygmomanometer and the mean arterial blood pressure was derived arithmetically. Blood pressures were measured with the patients in the lateral position.
The platelet count, haematocrit and haemoglobin were estimated before and after delivery. In vivo platelet function was assessed by a Duke bleeding time. Uniformity of measurement was achieved by restricting this data collection to only three of the collaborators. The Duke bleeding time, although less sensitive than the modified Ivy methods, was chosen as it does not cause scarring.8 In vitro platelet function was assessed by measuring Platelet Factor 3 (PF 3) and thromboxane B 2 . PF 3 is a component of the platelet membrane and thromboxane B2 is a platelet prostaglandin product. 8 Both are indirect means of assessing platelet aggregation and the release reaction. These were measured using a PAP 4 Stansen Aggregometer and COATEST Carby technique respectively.
We looked for evidence of fibrinolysis by measuring the substrate, fibrinogen, and the monoclonal D-dimer. 9 
RESULTS
The results for platelet count, haemoglobin and Duke bleeding time are summarised in Table 2 .
We found an overall incidence of thrombocytopenia (platelet count < 150X 10 9 /1) of 15% (6140 patients). Duke bleeding time was normal in all patients except one. This patient (#02) had severe preeclampsia with a platelet count of < 50 X 10 9 /1, a bleeding time of 13 minutes, a slightly decreased availability of PF 3, an elevated monoclonal D-dimer and was delivered by caesarean section at 29 weeks' gestation. Her 563 g offspring died subsequently. This patient also had a 3.4 gldl fall in haemoglobin after delivery.
The patients with moderate thrombocytopenia also had slightly greater falls in haemoglobin after delivery -a mean drop of 2 gldl as opposed to a mean fall of 1.2 gldl in non-thrombocytopenic patients) ( Table 2 ). As the serum iron levels measured by the iron FZ tests (Roche), in all our patients were normal (16±6. 7 molll), we feel that haemolysis was not a major factor in this fall in haemoglobin. Thus the fall in haemoglobin after delivery was used as a rough guide to overall blood loss.
Thromboxane B2 was normal in all patients studied. Platelet Factor 3 was also normal in all patients except one (see above). Evidence of fibrinolysis was noted in 21 % of preeclamptic patients. Seven of the 33 patients for whom the information was available (21.2%) had a monoclonal D-dimer > 0.2 mcglml (normal, < 0.2 mcg/ml) and nine of the 40 (23%) pre-eclamptic patients had low fibrinogen levels (mean 3.6±0.23 g/l). D-dimer and fibrinogen were normal in all pregnant controls. PI was normal in all patients studied. APTT was slightly prolonged in one (#13) patient (mean 32.8±4.5 seconds). The thrombin time was slightly prolonged in one (#14) patient. However, all other coagulation parameters in these patients were normal. A similar incidence of coagulation cascade abnormalities has been reported by Dube. 1o Serum uric acid was elevated in 57% of patients (mean 0.36±0.13 mmol/l) and 32% of patients had a slightly increased serum creatinine level. Both these indices point to some renal function impairment. Overall, 20% had some evidence of hepatic involvement: 8/40 had elevated ALT, 2/40 had elevated GGT and 1140 had mildly elevated bilirubin. Similar incidences of hepatic and renal involvement have been reported previously.ll All fasting serum iron levels were normal as were antithrombin III levels. In previous studies, increased serum iron and decreased antithrombin III have been associated with increased disease severity and a higher incidence of coagulopathy.12-14 Patients with positive lupus anticoagulant constitute a subset of patients likely to develop a more malignant form of pre-eclampsia. None of our patients had an elevated lupus coagulant (anti-cardiolipin antibody).ls.16 DISCUSSION One cause of pre-eclampsia is believed to be an imbalance of prostacyclin and thromboxane production. 17 The increase in thromboxane 'effect' leads to: 1. vasoconstriction with resultant hypertension, cerebral oedema and convulsions; 2. decreased uteroplacental blood flow; and 3. increased platelet aggregation and fibrin and platelet deposition, especially in placental, renal and liver beds. 11 This results in decreased renal and liver function, thrombocytopenia and, occasionally, disseminated intravascular coagulation. IS Thrombocytopenia has been reported to occur in 11-35% of patients with pre-eclampsia. I ,19 In this study we found a 15% incidence of thrombocytopenia overall. We noted that there is no correlation between platelet count and blood pressure (Table 3 ). There was also no correlation between platelet count and other indices of disease severity such as birth weight, serum iron, uric acid and liver function. The lack of the correlation between platelet count and birth weight is clearly seen in the scattergram (Figure 1 ). Thus, a low platelet count could be present even in patients with mild disease, indicating the need to do platelet counts on all patients with preeclampsia before performing a regional block.
In pre-eclampsia, there is increased platelet turnover with decreased platelet life span. 2 0-23 Several authors have also reported abnormal platelet function. 3, 24, 25 Kelton et al. 3 studied 26 pre-eclamptic patients and found a 34% incidence of thrombocytopenia. In that study, five of nine thrombocytopenic patients had a prolonged Simplate 11 bleeding time and four out of fifteen non-thrombocytopenic patients also had a prolonged bleeding time. Eleven of the 26 patients had decreased thromboxane B2 biosyn thesis.
They postulated a platelet function defect and required that a bleeding time be performed on all pre-eclamptic patients. Whigham et af.2 4 found that platelets from severely pre-eclamptic patients showed less response than normal to a variety of aggregating agents. They suggested that the platelets may have undergone previous aggregation in the microcirculation. Some platelets can aggregate temporarily and after releasing some of their active constituents, return to the peripheral circulation. Inglis 25 studied platelet activity (microaggregate formation, adenosine diphosphate aggregation and p-thromboglobulin release) and found increased platelet turnover but normal platelet function in fourteen preeclamptic patients.
Twenty-one per cent of our patients had evidence of fibrinolysis (as measured by D-dimer) and some had evidence of mild renal and liver dysfunction, supporting the theory of microaggregation and possible re-release. In our study, we found evidence of a platelet function defect in only one of 40 patients (2.5%). This patient also had severe thrombocytopenia. When we compare platelet count and bleeding time (Figure 2 ), our data is in agreement with the views of Fischbach and Fogdall. 26 Patients with normal platelet function have no prolongation of bleeding time until the platelet count falls below 100 X 10 9 /l. As the platelet count falls further, the bleeding time becomes progressively more prolonged. Such a distribution suggests that the prolongation of the bleeding time in our study may have been a direct consequence of thrombocytopenia rather than a platelet function defect. The remainder of our patients had normal platelet function as measured by Duke bleeding time, thromboxane B2 and Platelet Factor 3.
Thus the results of our study do not agree with those of Kelton et aP. No patient with a normal platelet count had evidence of platelet dysfunction. There are (Figure 3 shows the blood pressure distribution of our study population before, during and after delivery.) 2. Our population may be geographically, socio-economically and nutritionally different from that of Kelton et aU 
CONCLUSION
Our study suggests that a platelet count would be adequate as a screening test of suitability for regional blockade. If the platelet count is between 50 and 100 X 10 9 /1, a bleeding time is indicated. If the platelet count is less than 50 X 10 9 /1, the bleeding time will be prolonged as a result of the thrombocytopenia and so is unnecessary. Regional blockade is consequently contraindicated in patients with a platelet count of less than 50 X 10 9 11, or platelet count of between 50 and 100 X 10 9 /1 and a prolonged bleeding time.
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